Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilobelimab Alone or with Pembrolizumab in Resistant cSCC
NCT04812535Phase 2Terminated
- Sponsor
- InflaRx
- Start
- Mar 2021
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of vilobelimab in cutaneous squamous cell carcinoma (cSCC), sponsored by InflaRx. Started Mar 2021; status: terminated.
02
Drugs
vilobelimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04812535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04812535.